Bristol-Myers Squibb Compnay

Priyanka Apurva Madia

Guodong Chen

Jonathan Harry Davis

Aaron Paul Yamniuk

Michael L Gosselin

Mary Struthers

Achal Mukundrao Pashine

Richard Yu-Cheng Huang

Stephen Michael Carl

Michael Louis Doyle

Derek A Holmes

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Nucleic acids encoding anti-TREM-1 antibodies

Anti-TREM-1 antibodies and uses thereof

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R&#x3b1;), wherein IL2 or IL2R&#x3b1; comprises at least one fewer glycosylation site compared to native IL2 or native IL2R&#x3b1;. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc&#x3b3;Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Growing community of inventors

Franklin Park, NJ, United States of America

Priyanka Apurva Madia